Get the Stockscreener App
14.96
5.04%
-0.795
Pre-market:
14.95
-0.015
-0.10%
Tandem Diabetes Care Inc stock is traded at $14.96, with a volume of 1.99M.
It is down -5.04% in the last 24 hours and down -27.98% over the past month.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
See More
Previous Close:
$15.76
Open:
$15.74
24h Volume:
1.99M
Relative Volume:
0.80
Market Cap:
$1.03B
Revenue:
$1.01B
Net Income/Loss:
$-204.71M
P/E Ratio:
-4.876
EPS:
-3.0691
Net Cash Flow:
$-29.67M
1W Performance:
+16.73%
1M Performance:
-27.98%
6M Performance:
-29.68%
1Y Performance:
-27.50%
1-Day Range:
$14.94
$15.92
1-Week Range:
$12.83
$15.92
52-Week Range:
$9.98
$29.65
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Name
Tandem Diabetes Care Inc
Sector
Industry
Phone
858-366-6900
Address
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
14.96 | 1.08B | 1.01B | -204.71M | -29.67M | -3.0691 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Upgrade | Truist | Hold → Buy |
| Mar-17-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-23-26 | Upgrade | Lake Street | Hold → Buy |
| Feb-20-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-27-26 | Resumed | TD Cowen | Buy |
| Dec-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-21-25 | Resumed | Stifel | Hold |
| Sep-08-25 | Initiated | Oppenheimer | Outperform |
| Aug-12-25 | Upgrade | Citigroup | Sell → Neutral |
| Aug-07-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-09-25 | Downgrade | Citigroup | Neutral → Sell |
| Jun-16-25 | Initiated | Truist | Hold |
| Apr-10-25 | Initiated | Mizuho | Neutral |
| Mar-05-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Mar-03-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-28-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-02-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-06-24 | Initiated | Bernstein | Outperform |
| Oct-04-24 | Initiated | Goldman | Neutral |
| Oct-02-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-22-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-08-24 | Initiated | Canaccord Genuity | Buy |
| May-30-24 | Initiated | Redburn Atlantic | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-29-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-25-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Mar-26-24 | Upgrade | Stifel | Hold → Buy |
| Aug-04-23 | Downgrade | Citigroup | Buy → Neutral |
| May-05-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-24-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-26-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-15-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Aug-09-22 | Downgrade | Wells Fargo | Overweight → Underweight |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-25-21 | Initiated | Barclays | Underweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-20-20 | Initiated | Wells Fargo | Overweight |
| Jul-31-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jul-06-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-18-20 | Reiterated | Raymond James | Outperform |
| Apr-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-23-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-06-20 | Initiated | Raymond James | Outperform |
| Feb-04-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-18-19 | Initiated | Guggenheim | Buy |
| Oct-04-19 | Upgrade | UBS | Neutral → Buy |
| May-17-19 | Reiterated | BofA/Merrill | Neutral |
| May-13-19 | Initiated | SVB Leerink | Outperform |
| Mar-08-19 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-19 | Reiterated | BofA/Merrill | Neutral |
| Feb-27-19 | Reiterated | Lake Street | Buy |
| Nov-21-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-26-18 | Reiterated | Dougherty & Company | Buy |
| Sep-26-18 | Reiterated | Piper Jaffray | Overweight |
View All
Tandem Diabetes Care Inc Stock (TNDM) Latest News
Tandem Diabetes Care (TNDM) Is Up 16.7% After Beating Q3 Views And Reaffirming 2025 EBITDA Target – Has The Bull Case Changed? - Yahoo Finance
Is Tandem Diabetes Care Inc (TNDM) a Bargain After 5.1% Drop? GF Value Says Undervalued - GuruFocus
Tandem Diabetes Care (TNDM) chair emeritus reports new RSU grant and vesting - Stock Titan
[Form 4] TANDEM DIABETES CARE INC Insider Trading Activity - Stock Titan
Tandem Diabetes (TNDM) director reports 10,220 RSU grant and 8,759-share vesting - Stock Titan
Tandem Diabetes Care (TNDM) director receives 5,110 restricted stock units grant - Stock Titan
Tandem Diabetes (TNDM) director adds shares through RSU grant and vesting - Stock Titan
Director at Tandem Diabetes (NASDAQ: TNDM) adds RSUs and shares - Stock Titan
Tandem Diabetes (TNDM) director receives 10,220 RSU grant as prior award vests - Stock Titan
Tandem Diabetes (TNDM) director gets 10,220 RSUs as 8,759 vest - Stock Titan
Tandem Diabetes (TNDM) director Twomey reports RSU grant and 8,759-unit vesting - Stock Titan
Does Tandem Diabetes Care’s (TNDM) Expanded Incentive Plan Clarify Its Long‑Term Growth Priorities? - Sahm
Shareholders back charter changes and equity plan at Tandem Diabetes (NASDAQ: TNDM) - Stock Titan
Reasons to hold Tandem Diabetes stock in your portfolio for now - MSN
TNDM Technical Analysis | Trend, Signals & Chart Patterns | TANDEM DIABETES CARE INC (NASDAQ:TNDM) - ChartMill
Small-Cap Stocks to Avoid: Wyndham, KBR, and Tandem Diabetes Care AnalysisNews and Statistics - IndexBox
Tandem Diabetes’s SWOT analysis: stock faces competitive headwinds By Investing.com - Investing.com Nigeria
TNDM stock down following Q1 earnings & revenue beat, gross margin up - MSN
Tandem Diabetes’s SWOT analysis: stock faces competitive headwinds - Investing.com
Tandem Diabetes (NASDAQ: TNDM) Form 144: 266 RSUs slated for sale - Stock Titan
Tandem Diabetes Care Stock Down 23% But Insiders Still In US$84k Profit - 富途牛牛
Tandem Diabetes (TNDM) CTO reports RSU vesting, ESPP share purchase and tax withholding - Stock Titan
Tandem Diabetes (TNDM) EVP reports RSU exercises, tax share withholding and trust holdings - Stock Titan
Tandem Diabetes Care (TNDM) legal chief reports RSU vesting, tax withholding and ESPP purchase - Stock Titan
Tandem Diabetes (TNDM) COO logs RSU vesting, tax withholding and ESPP purchase - Stock Titan
Tandem Diabetes (TNDM) exec gains shares via RSU vesting and ESPP - Stock Titan
Tandem Diabetes Care (TNDM) CEO reports RSU vesting, ESPP buy and tax withholding - Stock Titan
Tandem Diabetes (TNDM) CFO exercises RSUs and ESPP, increases share holdings - Stock Titan
Tandem Diabetes (TNDM) EVP gets RSU shares while company withholds stock for taxes - Stock Titan
Silver Economy Investing: Why the Healthcare Giants Are in Focus - TradingView
TNDM Maintained by B of A Securities -- Price Target Lowered to $25 - GuruFocus
Tandem Diabetes Care Price Target Cut to $25.00/Share From $35.00 by B of A Securities - Moomoo
Tandem Diabetes’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
BofA Securities Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Cuts Target Price to $25 - Moomoo
Tandem Diabetes Care, Inc. Stock 12‑Month Price Target Cut to $30.8, Implies 140% Upside - TradingView
(TNDM) Volatility Zones as Tactical Triggers - Stock Traders Daily
Tandem Diabetes Care (TNDM) loses 26.5% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Tandem Diabetes Care, Inc. Files Form 8-K with SEC Detailing Company Information and NASDAQ Listing - Minichart
Tandem Diabetes Care to end employment of chief commercial officer By Investing.com - Investing.com Canada
Tandem Diabetes Care to end employment of chief commercial officer - Investing.com UK
Tandem Diabetes Care Announces Leadership Change, Strategy Unchanged - TipRanks
Tandem Diabetes Care IncMark Novara, evp and chief commercial officer, to be terminated without causeSEC filing - marketscreener.com
Mark Novara to Exit Tandem Diabetes Care as EVP & Chief Commercial Officer - TradingView
Tandem Diabetes (NASDAQ: TNDM) to terminate EVP & Chief Commercial Officer - Stock Titan
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up - TradingView
Tandem Diabetes Care Q1 earnings call highlights - MSN
Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold? - TradingView
Benchmark initiates coverage of Tandem Diabetes Care (TNDM) with hold recommendation - MSN
Transcript : Tandem Diabetes Care, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 02 - marketscreener.com
Why Tandem Diabetes (TNDM) Shares Are Trading Lower Today - Yahoo Finance
TNDM Initiated Coverage by Benchmark -- Rating Set to Hold - GuruFocus
Tandem Diabetes Care Inc Stock (TNDM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):